Diagnosis and management of differentiated thyroid cancer using molecular biology

Laryngoscope

Volumn 123, Issue 4, 2013, Pages 1059-1064

  Witt, Robert L ^a,c   Ferris, Robert L ^b   Pribitkin, Edmund A ^c   Sherman, Steven I ^d   Steward, David L ^e   Nikiforov, Yuri E ^f  

^a HELEN F GRAHAM CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

BRAF; differentiated thyroid cancer; Papillary thyroid cancer; PAX8 PPAR ; RAS; RET PTC

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN RET; RADIOACTIVE IODINE; RAS PROTEIN;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHERNOBYL ACCIDENT; CLINICAL PRACTICE; DIFFERENTIATED THYROID CANCER; FINE NEEDLE ASPIRATION BIOPSY; FOLLICULAR CARCINOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THYROID CARCINOMA; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA; HUMANS; MUTATION; PROGNOSIS; THYROID NEOPLASMS;

EID: 84875439015     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23838     Document Type: Review

References (44)

1. Gharib, H,. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr Pract 2004; 10: 31-39.
2. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J,. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Path 2005; 4: 541-46.
3. Gomez Saez JM,. Diagnostic usefulness of tumor markers in the thyroid cytological samples extracted by fine-needle aspiration biopsy. Endocr Metab Immune Dis Drug Targ 2010; 10: 47-56.
4. Bhaije F, Nikiforov YE,. Molecular analysis of thyroid tumors. Endocr Pathol 2011; 22: 126-33.
5. Kimura ET, Nikforova MN, Zhu A, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457.
6. Xing M,. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-262.
7. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-5404.
8. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE,. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006; 91: 3603-3610.
9. Nikiforov YE, Rowland JM, Bove KE, Moneforte-Munoz H, Fagan JA,. Distinct pattern of ret oncogene rearrangements in morphological variants in radiation induced and sporadic papillary thyroid cancers in children. Cancer Res 1997; 57: 1690-1694.
10. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE,. Molecular profile and clinically-pathologic features of the follicular variant of papillary thyroid cancer. An unusually high variance of RAS mutations. Am J Clin Pathol 2003; 120: 71-77.
11. Ezzat S, Zheng L, Kolenda, et al. Prevalence of activating ras mutation in morphologically characterized thyroid nodules. Thyroid 1996; 6: 409-416.
12. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8/PPARγ rearrangement in thyroid tumor: evidence for distinct molecular pathways for follicular thyroid carcinoma. J Clinical Endocrinol Metab 2003; 88; 2318-26.
13. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D,. Light-directed, spatially addressable parallel chemical synthesis. Science 1991; 251: 767-773.
14. Eszlinger M, Krohn K, Kukulska A, Jarzab B, Paschke R,. Perspectives and limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors. Endocrine Reviews 2007; 28: 322-338.
15. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
16. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
17. Nikiforova MN, Nikiforov YE,. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009; 19: 1351-1361.
18. Adeniran AJ, Theoharis C, Hui P, et al. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid 2011; 21: 717-723.
19. Kim SW, Lee JI, Kem J, et al. BRAF mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAF prevalent population. J Clin Endocrinol Metab 2010; 95: 3693-3700.
20. Musholt T, Fottner C, Weber M, et al. Detection of papillary carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg 2010; 34: 2595-2603.
21. Nikiforov YE, Steward D, Robinson-Smith TM,. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodule. J Clin Endocrinol Metab 2009; 94: 2092-2098.
22. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contributions of molecular testing thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol 2010; 118: 17-23.
23. Cantara S, Capezzone, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369.
24. Nikiforov YE, Ohori NP, Hodak S, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390-3397.
25. Ferraz C, Eszlinger M, Paschke R,. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab 2011; 96: 2016-26.
26. Chudova D, Wilde JI, Wang E, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010; 95: 5301-5309.
27. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. NEJM 2012; 1-11.
28. Kim SK, Hwang TS, Yoo YB, et al Surgical results of thyroid nodules according to a management guideline based on the BRAF (V600E) mutation status. J Clin Endocrinol Metab 2011; 96: 658-664.
29. Xing M, Clark D, Guan H, et al. The BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer J Clin Oncol 2009; 27: 2977-2982.
30. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009; 146: 1215-1223.
31. Tufano RP, Bishop J, Gaosong W,. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutations. Laryngoscope 2012; 122: 1634-1640.
32. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P,. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+I- targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-269.
33. Kim TH, Park YJ, Lim JA,. The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-73
34. Lin KL, Wang O, Zhang X, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma Ann Surg Oncol 2010; 17: 3294-3300.
35. Howell GM, Carty SE, Armstrong MJ, et al. Both BRAF V600E mutation and older age (>65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 2011; 18: 3566-3571.
36. Niemeier LA, Akatsu HK, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 2012; 118: 2069-2077.
37. Barollo S, Pennelli G, Vianello F, et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F]fluoro-2-deoxy- D-glucose uptake ability. Eur J Endocrinol 2010; 163: 659-663.
38. Soares P, Sobrinho-Simoes M,. Cancer: small papillary thyroid cancers-is BRAF of prognositc value? Nat Rev Endocrinol 2011; 7: 9-10.
39. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogen 2005; 24: 6646-6656.
40. Rivera M,., Ricarte-Filho J, Knauf, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Modern Pathology 2010; 23: 1191-1200.
41. Diuck DS, Klopper, JP, Diggans JC, et al. The impact of benign gene expression classifier test results on the endorinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid 2012; 22: 1-6.
42. Chiappetta G, Ferraro A, Vuttariello E, et al. HMGA2mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 2008; 44: 1015-1021.
43. Nikiforova MN, Chiosea SI, Nikiforov YE,. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 2009; 20: 85-91.
44. Yip L, Delly L, Shuai Y, et al. MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma. Ann Surg Oncol 2011; 18: 2035-2041.